CASI Pharmaceuticals Inc.
| NASDAQ: CASI | Healthcare / Biotechnology / USA |
| 1.64 | -0.0889 | -5.14% | Vol 3.55K | 1Y Perf 109.11% |
| Mar 24th, 2023 16:00 DELAYED |
| BID | 0.6520 | ASK | 1.95 | ||
| Open | 1.66 | Previous Close | 1.73 | ||
| Pre-Market | - | After-Market | 1.72 | ||
| - - | 0.08 4.88% |
| Target Price | 10.00 | Analyst Rating | Strong Buy 1.00 | |
| Potential % | 509.76 | Finscreener Ranking | ★★★★★ 58.29 | |
| Insiders Trans % 3/6/12 mo. | 100/100/100 | Value Ranking | ★★ 46.58 | |
| Insiders Value % 3/6/12 mo. | 100/100/100 | Growth Ranking | ★★ 46.78 | |
| Insiders Shares Cnt. % 3/6/12 mo. | 100/100/100 | Income Ranking | — - | |
| Price Range Ratio 52W % | 0.19 | Earnings Rating | Strong Sell | |
| Market Cap | 203.27M | Earnings Date | 27th Mar 2023 | |
| Alpha | -0.02 | Standard Deviation | 0.27 | |
| Beta | 1.23 |
Today's Price Range 1.601.69 | 52W Range 1.45103.00 | 5 Year PE Ratio Range -15.20-6.90 |
Summary:
Sell
| Technical Indicators: | Neutral |
| Moving Averages: | Strong Sell |
| Performance | |||
|---|---|---|---|
| 1 Week | -2.38% | ||
| 1 Month | -12.77% | ||
| 3 Months | 7.89% | ||
| 6 Months | -37.40% | ||
| 1 Year | 109.11% | ||
| 3 Years | -21.53% | ||
| 5 Years | -58.90% | ||
| 10 Years | -26.13% |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | -36.87 | |||
ROE last 12 Months | -40.09 | |||
ROA (5Y Avg) | -18.87 | |||
ROA last 12 Months | -22.25 | |||
ROC (5Y Avg) | -38.34 | |||
ROC last 12 Months | -35.03 | |||
Return on invested Capital Q | -7.64 | |||
Return on invested Capital Y | -6.45 | |||
Assets Turnover | 0.20 | |||
Receivables Turnover | 2.70 |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -1.00 | ||||
| 0.44 | ||||
| 8.50 | ||||
| - | ||||
| -1.20 | ||||
| -2.03 | ||||
| 0.44 | ||||
| 4.54 | ||||
| -1 146 680.00 | ||||
| Forward PE | -0.81 | |||
| PEG | - |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 1.50 | ||||
| 1.90 | ||||
| 0.01 | ||||
| 0.07 | ||||
| 165.00 | ||||
| Leverage Ratio | 1.90 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 58.40 | ||||
| -88.50 | ||||
| -83.30 | ||||
| - | ||||
| -75.11 |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 27.85M | ||||
| 0.22 | ||||
| - | ||||
| - |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q03 2022 | -0.51 | -0.38 | 25.49 |
| Q02 2022 | -0.65 | -0.56 | 13.85 |
| Q01 2022 | -1.00 | -0.60 | 40.00 |
| Q04 2021 | -0.60 | -0.40 | 33.33 |
| Q03 2021 | -0.60 | -0.70 | -16.67 |
| Q02 2021 | -0.90 | -0.50 | 44.44 |
| Q01 2021 | -0.50 | -1.10 | -120.00 |
| Q04 2020 | -0.07 | -0.12 | -71.43 |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| 12/2022 QR | -0.61 | -74.29 | Negative |
| 12/2022 FY | -2.16 | -53.19 | Negative |
| 3/2023 QR | -0.57 | -128.00 | Negative |
| 12/2023 FY | -2.05 | -184.72 | Negative |
| Next Report Date | 27th Mar 2023 |
| Estimated EPS Next Report | -0.61 |
| Estimates Count | 1 |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 3.55K |
| Shares Outstanding | 123.94K |
| Shares Float | 11.05M |
| Trades Count | 50 |
| Dollar Volume | 5.78K |
| Avg. Volume | 18.77K |
| Avg. Weekly Volume | 18.62K |
| Avg. Monthly Volume | 12.39K |
| Avg. Quarterly Volume | 25.30K |
CASI Pharmaceuticals Inc. (NASDAQ: CASI) stock closed at 1.64 per share at the end of the most recent trading day (a -5.14% change compared to the prior day closing price) with a volume of 3.55K shares and market capitalization of 203.27M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 125 people. CASI Pharmaceuticals Inc. CEO is Wei-Wu He.
The one-year performance of CASI Pharmaceuticals Inc. stock is 109.11%, while year-to-date (YTD) performance is -8.38%. CASI stock has a five-year performance of -58.9%. Its 52-week range is between 1.45 and 103, which gives CASI stock a 52-week price range ratio of 0.19%
CASI Pharmaceuticals Inc. currently has a PE ratio of -1.00, a price-to-book (PB) ratio of 0.44, a price-to-sale (PS) ratio of 8.50, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -22.25%, a ROC of -35.03% and a ROE of -40.09%. The company’s profit margin is -75.11%, its EBITDA margin is -83.30%, and its revenue ttm is $27.85 Million , which makes it $0.22 revenue per share.
Of the last four earnings reports from CASI Pharmaceuticals Inc., there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $-0.61 for the next earnings report. CASI Pharmaceuticals Inc.’s next earnings report date is 27th Mar 2023.
The consensus rating of Wall Street analysts for CASI Pharmaceuticals Inc. is Strong Buy (1), with a target price of $10, which is +509.76% compared to the current price. The earnings rating for CASI Pharmaceuticals Inc. stock is Strong Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
CASI Pharmaceuticals Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
CASI Pharmaceuticals Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 17.43, ATR14 : 0.11, CCI20 : -118.13, Chaikin Money Flow : -0.09, MACD : -0.07, Money Flow Index : 42.48, ROC : -17.17, RSI : 36.61, STOCH (14,3) : 9.82, STOCH RSI : 0.46, UO : 38.84, Williams %R : -90.18), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of CASI Pharmaceuticals Inc. in the last 12-months were: James Z. Huang (Buy at a value of $1 009 138), Wei-Wu He (Buy at a value of $272 506)
CASI Pharmaceuticals Inc.
CASI Pharmaceuticals Inc is a biopharmaceutical company that focuses on commercializing innovative therapeutics and pharmaceutical products. The products include injections for patients who are suffering from leukemias and lymphomas. The EVOMELA injection is used as a conditioning treatment before autologous stem cell transplant for patients with multiple myeloma. The company products include CID-103, CNCT19, EVOMELA, MARQIBO, ZEVALIN, ENMD-2076 and others. The majority of the revenue is generated from the product sales of EVOMELA. The company primarily operates in the United States, Canada, China and other parts of the world.
CEO: Wei-Wu He
Telephone: +1 240 864-2600
Address: 9620 Medical Center Drive, Rockville 20850, MD, US
Number of employees: 125
